Table 2.

Average Number of Days’ Exposure to and Cost of Study Simvastatin plus Ezetimibe per Patient, by CVD Risk and CKD Stage at Randomization

	Study Simvastatin plus Ezetimibe		Cost to Achieve LDL-C Reductions Observed in SHARPa
Days	Cost
By 5-year risk of CVD
<10%	1,400 ± 18	£1,665 ± £21	£1,570 ± £20
10%-<20%	1,236 ± 17	£1,471 ± £20	£1,380 ± £19
≥20%	1,038 ± 15	£1,235 ± £18	£1,137 ± £16
By CKD stage
3b	1,333 ± 18	£1,586 ± £22	£1,454 ± £20
4	1,289 ± 17	£1,534 ± £21	£1,449 ± £20
5c	1,064 ± 26	£1,266 ± £31	£1,182 ± £29
On dialysis	1,077 ± 18	£1,282 ± £21	£1,214 ± £20
All patients	1,200 ± 10	£1,428 ± £12	£1,319 ± £11

Note: Values are given as average ± standard error. Simvastatin plus ezetimibe at UK £1.19 per day (2015).

Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; SHARP, Study of Heart and Renal Protection.

^aActual use of study simvastatin plus ezetimibe treatment adjusted to the use needed to achieve the LDL cholesterol level reductions observed in SHARP in the absence of other lipid-lowering treatments. For example, 57% of participants on dialysis therapy at randomization allocated to simvastatin plus ezetimibe were taking their study treatment at 2.5 years (and average study simvastatin plus ezetimibe cost for a participant on dialysis therapy at randomization was £1,282), but net use of any (including nonstudy) lipid-lowering treatment between study treatment arms at 2.5 years was 54%. Therefore, the cost of simvastatin plus ezetimibe needed to achieve the observed LDL cholesterol levels in this patient group was calculated as £1,282 × [54%/57%] = £1,214.

^b83% of participants in this category with CKD stage 3b (estimated glomerular filtration rate of 30-<45 mL/min/1.73 m²).

^cNot on dialysis therapy.